Tags

Type your tag names separated by a space and hit enter

Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected].
Atheroscler Suppl 2013; 14(2):243-51AS

Abstract

BACKGROUND

Although omega-3 fatty acids have well documented properties which would reduce the cardiovascular (CV) disease risk, the evidence from randomized controlled trials (RCTs) remains inconclusive. We performed a meta-analysis of the available RCTs for investigating the CV preventive effect of administrating at least 1 gram/day, and for at least 1 year, omega-3 fatty acid supplements to patients with existing CV disease.

METHODS

RCTs published up to March 2013 were searched from PubMed, EMBASE, and the Cochrane Library. Two of us independently reviewed and selected eligible trials.

RESULTS

Of 360 articles retrieved, 11 randomized, double-blind, placebo controlled trials fulfilling inclusion criteria, overall involving 15,348 patients with a history of CV disease, were considered in the final analyses. No statistically significant association was observed for all-cause mortality (RR, 0.89; 95% CI, 0.78 to 1.02) and stroke (RR, 1.31; 95% CI, 0.90 to 1.90). Conversely, statistically significant protective effects were observed for cardiac death (RR, 0.68; 95% CI, 0.56 to 0.83), sudden death (RR, 0.67; 95% CI, 0.52 to 0.87), and myocardial infarction (RR, 0.75; 95% CI, 0.63 to 0.88).

CONCLUSION

Overall, our results supply evidence that long-term effect of high dose omega-3 fatty acid supplementation may be beneficial for the onset of cardiac death, sudden death and myocardial infarction among patients with a history of cardiovascular disease.

Authors+Show Affiliations

Centre of Epidemiology and Preventive Pharmacology-SEFAP, Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy. sefap@unimi.itNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

23958480

Citation

Casula, Manuela, et al. "Long-term Effect of High Dose Omega-3 Fatty Acid Supplementation for Secondary Prevention of Cardiovascular Outcomes: a Meta-analysis of Randomized, Placebo Controlled Trials [corrected]." Atherosclerosis. Supplements, vol. 14, no. 2, 2013, pp. 243-51.
Casula M, Soranna D, Catapano AL, et al. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler Suppl. 2013;14(2):243-51.
Casula, M., Soranna, D., Catapano, A. L., & Corrao, G. (2013). Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. Atherosclerosis. Supplements, 14(2), pp. 243-51. doi:10.1016/S1567-5688(13)70005-9.
Casula M, et al. Long-term Effect of High Dose Omega-3 Fatty Acid Supplementation for Secondary Prevention of Cardiovascular Outcomes: a Meta-analysis of Randomized, Placebo Controlled Trials [corrected]. Atheroscler Suppl. 2013;14(2):243-51. PubMed PMID: 23958480.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. AU - Casula,Manuela, AU - Soranna,Davide, AU - Catapano,Alberico L, AU - Corrao,Giovanni, PY - 2013/8/21/entrez PY - 2013/8/21/pubmed PY - 2014/3/19/medline KW - Cardiovascular disease KW - Meta-analysis KW - Omega-3 fatty acid KW - Secondary prevention KW - Supplementation SP - 243 EP - 51 JF - Atherosclerosis. Supplements JO - Atheroscler Suppl VL - 14 IS - 2 N2 - BACKGROUND: Although omega-3 fatty acids have well documented properties which would reduce the cardiovascular (CV) disease risk, the evidence from randomized controlled trials (RCTs) remains inconclusive. We performed a meta-analysis of the available RCTs for investigating the CV preventive effect of administrating at least 1 gram/day, and for at least 1 year, omega-3 fatty acid supplements to patients with existing CV disease. METHODS: RCTs published up to March 2013 were searched from PubMed, EMBASE, and the Cochrane Library. Two of us independently reviewed and selected eligible trials. RESULTS: Of 360 articles retrieved, 11 randomized, double-blind, placebo controlled trials fulfilling inclusion criteria, overall involving 15,348 patients with a history of CV disease, were considered in the final analyses. No statistically significant association was observed for all-cause mortality (RR, 0.89; 95% CI, 0.78 to 1.02) and stroke (RR, 1.31; 95% CI, 0.90 to 1.90). Conversely, statistically significant protective effects were observed for cardiac death (RR, 0.68; 95% CI, 0.56 to 0.83), sudden death (RR, 0.67; 95% CI, 0.52 to 0.87), and myocardial infarction (RR, 0.75; 95% CI, 0.63 to 0.88). CONCLUSION: Overall, our results supply evidence that long-term effect of high dose omega-3 fatty acid supplementation may be beneficial for the onset of cardiac death, sudden death and myocardial infarction among patients with a history of cardiovascular disease. SN - 1878-5050 UR - https://www.unboundmedicine.com/medline/citation/23958480/Long_term_effect_of_high_dose_omega_3_fatty_acid_supplementation_for_secondary_prevention_of_cardiovascular_outcomes:_A_meta_analysis_of_randomized_placebo_controlled_trials_[corrected]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-5688(13)70005-9 DB - PRIME DP - Unbound Medicine ER -